Shopping Cart
- Remove All
- Your shopping cart is currently empty
Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $970 | Backorder |
Description | Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD). |
In vitro | Zevaquenabant simultaneously inhibits CB1 receptors and iNOS in peripheral organs [1]. |
In vivo | Zevaquenabant (3 mg/kg; p.o.; for 28 days) significantly enhances renal morphology and function in diet-induced obese mice[1]. Using 6-week-old male C57Bl/6J mice as an animal model for diet-induced obesity[1], the administration of Zevaquenabant markedly improved kidney health and performance. |
Alias | (S)-MRI-1867 |
Molecular Weight | 547.98 |
Formula | C25H21ClF3N5O2S |
Cas No. | 1998760-00-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.